Taf + Emtricitabine + Elvitegravir + Cobicistat Generics - Manufacturers & Suppliers
Genvoya(US & EU)
| Product/Composition:- | TAF + Emtricitabine + Elvitegravir + Cobicistat |
|---|---|
| Strength:- | Elvitegravir – 150 mg + Cobicistat – 150 mg + Emtricitabine – 200 mg + TAF – 10 mg |
| Form:- | Tablet |
| Reference Brands:- | Genvoya(US & EU) |
| MOQ | As per the manufacturer batch size |
| Get Quote Send Enquiry on WhatsApp | |
Genvoya is a once-daily HIV-1 treatment combining TAF, Emtricitabine, Elvitegravir, and Cobicistat. It provides strong viral suppression with better kidney and bone safety than older TDF-based options. FDA and EMA approved.
Genvoya is a once-daily, fixed-dose combination of Tenofovir Alafenamide (TAF) 10 mg, Emtricitabine 200 mg, Elvitegravir 150 mg, and Cobicistat 150 mg, used for the treatment of HIV-1 infection. Approved by the US FDA and EMA, Genvoya offers potent viral suppression with improved renal and bone safety compared to older TDF-based regimens like Stribild. It is indicated for treatment-naïve adults and adolescents (≥12 years, ≥35 kg) with no resistance to its components. The inclusion of Cobicistat enhances Elvitegravir and TAF levels, enabling effective once-daily dosing. Genvoya simplifies HIV therapy and improves adherence through its single-tablet formulation.